Nakamura Itaru, Yamaguchi Tetsuo, Aoki Kotaro, Miura Yuri, Sato Satoko, Fujita Hiroaki, Watanabe Hidehiro
Department of Infection Prevention and Control, Tokyo Medical University Hospital, Tokyo, Japan.
Department of Microbiology and Infectious Diseases, Faculty of Medicine, Toho University, Tokyo, Japan
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01746-20.
We applied combination antibiotic therapy to treat vertebral osteomyelitis and a psoas abscess caused by glycopeptide-intermediate (MIC, 2 μg/ml) and daptomycin-nonsusceptible (>2 μg/ml) methicillin-resistant The Etest synergy test showed the largest synergistic effects for imipenem/cilastatin and fosfomycin. Whole-gene sequencing showed amino acid changes in SA0802, SA1193 (), and SA1531 (). Four weeks of combination treatment using imipenem/cilastatin (1.5 g per day) and fosfomycin (4.0 g per day) resulted in clinical improvement.
我们应用联合抗生素疗法治疗由糖肽中介（最低抑菌浓度，2μg/ml）和对达托霉素不敏感（>2μg/ml）的耐甲氧西林金黄色葡萄球菌引起的椎体骨髓炎及腰大肌脓肿。Etest协同试验显示亚胺培南/西司他丁和磷霉素具有最大的协同效应。全基因测序显示SA0802、SA1193（）和SA1531（）存在氨基酸变化。使用亚胺培南/西司他丁（每日1.5g）和磷霉素（每日4.0g）进行四周的联合治疗使病情得到临床改善。
